MIR6859-4

Across TCGA pan-cancer cohorts, MIR6859-4 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MIR6859-4’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MIR6859-4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MIR6859-4 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.

LIHC, HNSC, and COAD are the cancer types where MIR6859-4 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR6859-4 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.318	.010	4	view →
HNSC	Male	II,III,IV	+0.233	.038	4	view →
COAD	All	III,IV	−0.560	.007	3	view →
KIRC	All	All	+0.184	.007	3	view →
CHOL	All	All	+0.687	.049	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MIR6859-4–LIHC

Open the LIHC breakdown →